Cellectar Biosciences (CLRB)
(Real Time Quote from BATS)
$2.14 USD
+0.04 (1.91%)
Updated Sep 19, 2024 01:17 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLRB 2.14 +0.04(1.91%)
Will CLRB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLRB
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131
What's in Store for Cooper Companies (COO) in Q3 Earnings?
CLRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
Here's Why You Should Retain Accuray (ARAY) Stock for Now
Other News for CLRB
Perspective gets FDA fast track status for radiopharmaceutical VMT01
Perspective gets FDA fast track status for radiopharmaceutical VMT101
Novartis expands U.S. radiopharma production amid rising competition
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom?s Macroglobulinemia
Cellectar to Restate Previously Issued Financial Statements ? Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq